Pipeline

Designated Asia-Pacific Regions

Designated Asian Regions

Mainland China, Hong Kong, Macau and Taiwan

China

Overseas

Product	Rights Authorized Region*	Indication	Clinical Trial Approval	Clinical Trial for Registration	Marketing Application	Marketed	Major Marketed Regions*
							CN	US	EU	JP
Diazepam Nasal Spray		For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older					√ 2023.6	√
Tildrakizumab Injection (Biological Agent)		For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy					√ 2023.5	√	√	√
Methotrexate Injection		Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids					√ 2023.3		√
		Active rheumatoid arthritis in adult patients					√ 2024.7		√	√
Methylthioninium Chloride Enteric-coated Sustained-release Tablets		A diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy					√ 2024.6		√
Ruxolitinib cream		Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older					Approved for marketing in Macau (2024.4) and HK (2024.11)	√	√
		Topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable						√
Desidustat Tablets		For treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients
Cyclosporine Eye Drops 0.09%		Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye)						√	√
Latanoprost Eye Drops		Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension						√
ZUNVEYL	**	For the treatment of mild-to-moderate dementia of the Alzheimer’s type						√
Levetiracetam XR Tablet		Adjunctive therapy for the treatment of partial-onset seizures						√
BCG for Intravesical Instillation (Biological Agent)	***	Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence							√

* Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region, CMS has NO development, commercialization or other product rights in unauthorized regions. Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
** Rights authorized region of ZUNVEYL are Asia (excluding Japan and the Middle East), Australia and New Zealand.
*** Taiwan is not included in the rights authorized region of BCG for Intravesical Instillation.
Updated as at 17 March 2025